Deutsche Bank Maintains Buy On Avanir Pharmaceuticals Following CTAD Conference

In a research note issued today, Deutsche Bank analyst Alethia Young maintained a Buy rating on Avanir Pharmaceuticals (NASDAQ:AVNR) with a $17 price target, following numerous presentations of AVP-925 data for Alzheimer’s dementia and PBA in dementia patients at the CTAD conference this past Friday and Saturday.

Young noted, “There was significant focus at this meeting on AVP-923 and AD agitation. In general, excitement for new emerging agitation treatments is high. Docs believe that the agitation space is entering a new era with an increased understanding of the neurobiology behind agitation in AD. Doctors still view the Avanir data as shocking and impressive.”

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Alethia Young has a total average return of 2.4% and a 55.6% success rate. Young has a -1.1% average return when recommending AVNR, and is ranked #1639 out of 3393 analysts.





Stay Ahead of Everyone Else

Get The Latest Stock News Alerts